Bispecific Antibody Targeting Claudin18.2 and 4-1BB
Pivotal Phase 3 Trial Planned for Q4 2026
Phase 1b Data to Be Presented at a Global Conference in the Second Half of the Year

ABL Bio announced on June 17 that Givastomig (ABL111), a bispecific antibody immuno-oncology therapy co-developed with the U.S. biotechnology company Novabrigde Biosciences, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).


ABL Bio's First-Line Gastric Cancer Drug Candidate Granted FDA Fast Track Designation View original image

The Fast Track program is designed to expedite the development and review of new drug candidates that have the potential to address unmet medical needs in life-threatening or serious diseases. Designated candidates are eligible for closer consultation with the FDA during development and, if certain criteria are met, can benefit from accelerated review procedures such as rolling review.


Givastomig is a bispecific antibody that simultaneously targets Claudin18.2, a protein expressed on the surface of cancer cells, and 4-1BB, which is involved in immune cell activation. It is currently being developed for patients with Claudin18.2-positive, HER2-negative advanced or metastatic gastric cancer. A Phase 2 clinical trial is underway to evaluate combination therapy with the chemotherapy regimen FOLFOX and the PD-1 inhibitor nivolumab.


Claudin18.2 is a target protein expressed in certain solid tumors, including gastric cancer, and has recently become the focus of active therapeutic development. In 2024, the Claudin18.2-targeted antibody therapy zolbetuximab received FDA approval in combination with chemotherapy, expanding the related market.


ABL Bio and Novabridge reported that the combination therapy with Givastomig demonstrated antitumor activity, safety, and tolerability in Phase 1b clinical trials. The two companies plan to release detailed Phase 1b data at a global conference in the second half of this year and aim to initiate a pivotal Phase 3 trial in the fourth quarter of 2026.



Lee Sanghoon, CEO of ABL Bio, stated, "Givastomig demonstrated treatment responses across various patient groups expressing Claudin18.2 in the Phase 1b trial. We expect the FDA Fast Track designation will accelerate development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing